Generic Name
Irinotecan HclPacks Price
- Inj 100 mg (066187): 1 Vialx5 ml: 6056.25: 7125.00
- Inj 40 mg(066186): 1 Vialx2 ml: 2550.00: 3000.00
Irinotecan
Therapeutic Group
Anti-neoplasticsIndication Dosage
Irinotecan HCl is indicated for the treatment of certain types of cancer. It is commonly used in the management of metastatic colorectal cancer when other treatments have not been effective. Additionally, Irinotecan HCl may be prescribed for the treatment of small-cell lung cancer when used in combination with other chemotherapy agents.
Metastatic Colorectal Cancer In Combination With Fluorouracil And Folinic Acid Or As Monotherapy When Treatment Containing Fluorouracil Has Failed, Treatment of Epidermal Growth Factor Receptor-expressing Metastatic Colorectal Cancer After Failure Of chemotherapy That Has Included Irinotecan (in combination With Cetuximab), First-line Treatment Of metastatic Carcinoma Of The Colon Or Rectum (in combination With Fluorouracil, Folinic Acid Andbevacizumab Or Capecitabinewith Or Without Bevacizumab):
By IV Infusion:
- Adult: 350 Mg/m2 Over 30-90 Min Every 3 Week. If the Patient Develops Severe Neutropenia Or Severe Diarrhoea Reduce the Dose To 300 Mg/m, And Then 250 Mg/m, In Subsequent Cycles. Consult Product Literature. Continue Treatment Until Disease Progression Or Unacceptable Toxicity.
- Children: Not Recommended.
Content
- Inj Per ml: Irinotecan Hydrochloride Trihydrate 20mg; Solution. 2 ml (40mg) And 5 ml(100mg) Vial,
Pregnancy
Positive Evidence Of Risk: Avoid
Stability
- Topoisomerase 1 Inhibitor
Contra Indications
- Chronic Inflammatory Bowel Disease, Bowel Obstruction, Hepatic Impairment, Renal Impairment, Severe Myelosuppression.
Precautions
- Chronic Inflammatory Bowel Disease, Bowel Obstruction, Hepatic Impairment, Renal Impairment, Severe Myelosuppression.
Lactation
- Contraindicated. Discontinue Breast-feeding
Side Effects
- Interstitial Pulmonary Disease
- Acute Cholinergic Syndrome And Delayed Diarrhoea (consult Product Literature)
- Alopecia
- Anorexia
- Asthenia
- Bone-marrow Suppression
- Extravasation
- Gi Effects
- Hyperuricaemia
- Myelosuppression(dose Limiting)
- Nausea
- Oral Mucositis
- Thromboembolism
- Tumourlysis Syndrome
- Vomiting
Available Brands
Author
Shahid Arif